Biopharmaceutical company focused on creating medicines for patients suffering from serious respiratory diseases.
Theravance Biopharma, Inc., a prominent biopharmaceutical company based in George Town, the Cayman Islands, specializes in the discovery, development, and commercialization of innovative respiratory medicines across global markets including the United States, Europe, and Asia.
The company's flagship product, YUPELRI, stands out as a once-daily, nebulized long-acting muscarinic antagonist specifically designed for managing chronic obstructive pulmonary disease (COPD). Beyond YUPELRI, Theravance Biopharma boasts a diverse product portfolio that includes Izencitinib, a gut-selective pan-Janus kinase (JAK) inhibitor currently advancing through Phase IIb/III clinical trials. Izencitinib targets multiple conditions such as rheumatoid arthritis, myelofibrosis, ulcerative colitis, and inflammatory intestinal diseases like Crohn's disease.
In addition to Izencitinib, the company's pipeline features Ampreloxetine, an investigational norepinephrine reuptake inhibitor that recently completed a Phase III study for neurogenic orthostatic hypotension. Nezulcitinib, another promising candidate, is a lung-selective, nebulized JAK inhibitor currently in Phase II development for treating acute lung injury in hospitalized COVID-19 patients.
Theravance Biopharma also leads in exploring innovative treatments like Inhaled ALK5i, a Phase I anti-fibrotic agent targeting idiopathic pulmonary fibrosis, and TD-5202, an orally administered, gut-selective, irreversible JAK3 inhibitor in Phase I clinical trials for inflammatory intestinal diseases. Further bolstering its portfolio are marketed products such as TRELEGY, indicated for COPD and asthma, alongside investigational therapies like Velusetrag for gastrointestinal motility disorders and Selective 5-HT4 Agonists.
Founded in 2013, Theravance Biopharma continues to expand its reach and impact through strategic licensing and collaboration agreements with key industry players including Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. With a steadfast commitment to innovation and therapeutic advancement, the company remains at the forefront of addressing critical medical needs worl dwide.